Forest Laboratories and partner AstraZeneca are ready to start Phase III clinical testing of CAZ-AVI, a superbug-fighting antibiotic that combines avibactam and ceftazidime. The drug will be tested on hospitalized patients with urinary tract or abdominal infection caused
by gram-negative bacteria. The drugmakers aim for a regulatory submission in 2014.

Full Story:

Related Summaries